Tyrosine News and Research

RSS

Cancer Research UK and AstraZeneca announce innovative deal for promising anti-cancer compound

Cancer Research UK and Cancer Research Technology (CRT) - the charity's development and commercialisation arm - today announced an innovative new arrangement to progress into clinical development a potential anti-cancer compound from AstraZeneca.

19 May 2008

Study shows how T cell's machinery dials down autoimmunity

A St. Jude Children's Research Hospital study shows that T cells, the body's master immune regulators, do not use simple on/off switches to govern the cellular machinery that regulates their development and function. Rather, they possess sophisticated molecular controls that enable them to adjust their function with exquisite precision. Such subtle adjustment enables T cells to modulate their development and function, including avoiding autoimmunity

12 May 2008

Arsenic-based agent shown to help eradicate leukemia-initiating cells

In both leukemia and solid tumors, there exists among the multitude of warrior cancer cells a small subgroup that work undercover, patiently lying in wait to launch their attacks. Known as either cancer initiating cells (CICs) or leukemia initiating cells (LICs), these stealth populations are impervious to conventional chemotherapy and undaunted by targeted cancer therapies. When a leukemia patient relapses following a period of remission, it is the LICs that bear responsibility for the disease's reemergence.

12 May 2008

Epidermal growth factor receptor protects cancer cells from starving

A growth factor receptor found abundantly on the surface of cancer cells and long known to fuel cancer growth also protects tumor cells from starvation by a newly identified mechanism, researchers at The University of Texas M. D. Anderson Cancer Center report in the May 5 issue of Cancer Cell.

5 May 2008

Mutation database helps personalized treatment of lung cancer

A groundbreaking free tool to help oncologists choose the best therapies for patients with non-small-cell lung cancer has been launched this week by scientists at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) in Geneva, Switzerland.

26 Apr 2008

Herceptin and chemotherapy improves response rates without major adverse effects in HER2 breast cancer

Women with a particularly aggressive form of breast cancer seem to do better if they are treated with a combined anthracycline and taxane chemotherapy regimen before surgery, together with trastuzumab (Herceptin) before and after surgery, according to results from the largest multi-centre trial to investigate this treatment.

18 Apr 2008

New type of drug shrinks primary breast cancer tumours significantly in just six weeks

A drug that targets the cell surface receptors that play an important role in many types of cancer can bring about significant tumour regression in breast cancer after only six weeks of use, a scientist told the 6th European Breast Cancer Conference (EBCC-6) (Thursday 17 April).

17 Apr 2008

Treatment with sunitinib slows tumor growth and spread of liver cancer

Treatment with sunitinib slows tumor growth and reduces the risk of metastasis in patients with hepatocellular carcinoma, an aggressive cancer of the liver, researchers report.

15 Apr 2008

Compound found in soybeans may halt spread of prostate cancer

A compound found in soybeans almost completely prevented the spread of human prostate cancer in mice, according to a study published in the March 15 issue of Cancer Research, a journal of the American Association for Cancer Research.

17 Mar 2008

Study explains fundamental process of tumor growth

Nearly 80 years ago, scientist Otto Warburg observed that cancer cells perform energy metabolism in a way that is different from normal adult cells.

14 Mar 2008

Study helps explain how tumor cells rapidly grow and proliferate

Nearly 80 years ago, scientist Otto Warburg observed that cancer cells perform energy metabolism in a way that is different from normal adult cells.

13 Mar 2008

ImClone Systems enrols first patient in clinical trial of IMC-1121B to treat liver cancer

ImClone Systems Incorporated has announced that it has enrolled the first patient in a disease-directed Phase II clinical trial of IMC-1121B to treat patients with advanced hepatocellular carcinoma (liver cancer).

26 Feb 2008

Gene therapy - immune system discovery may lead to effective treatment for glioblastoma multiforme

A new gene therapy approach that attracts and "trains" immune system cells to destroy deadly brain cancer cells also provides long-term immunity, produces no significant adverse effects and -- in the process of destroying the tumor -- promotes the return of normal brain function and behavioral skills, according to a study conducted by researchers at Cedars-Sinai Medical Center's Board of Governors Gene Therapeutics Research Institute.

20 Feb 2008

Sunitinib may be associated with cardiac toxicity

Another FDA-approved targeted cancer drug, sunitinib (SutentTM, Pfizer), may be associated with cardiac toxicity, report researchers at Children's Hospital Boston, Dana-Farber Cancer Institute (Boston), and Thomas Jefferson University (Philadelphia).

17 Dec 2007

Profound immune system discovery opens door to halting destruction of lupus

A researcher funded by the Lupus Research Institute (LRI) has discovered an entirely new and powerful molecular switch that controls the inflammatory response of the immune system.

14 Dec 2007

Molecular 'trip switch' shuts down inflammatory response

Like a circuit breaker that prevents electrical wiring from overheating and bringing down the house, a tiny family of three molecules stops the immune system from mounting an out-of-control, destructive inflammatory response against invading pathogens, researchers at the Salk Institute for Biological Studies have found.

14 Dec 2007

Bosutinib safe, effective for chronic myelogenous leukemia

A new drug for chronic myelogenous leukemia works for patients who have developed resistance to frontline therapy and causes fewer side effects than other medications in its class, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports at the 49th annual meeting of the American Society of Hematology.

12 Dec 2007

Data confirm Dasatinib's effectiveness in resistant chronic myelogenous leukemia

Updated clinical trial results show that the drug dasatinib (Sprycel) continues to be highly effective in patients with chronic myelogenous leukemia who were unable to tolerate Gleevec or who developed resistance to it, reports a team led by researchers at Dana-Farber Cancer Institute.

12 Dec 2007

New test for targeted therapy in acute myeloid leukemia

Oregon Health & Science University Cancer Institute researcher Jeff Tyner, Ph.D., has created a way to identify proteins that are candidates for targeted therapy in acute myeloid leukemia using an assay that yields results in just four days.

10 Dec 2007

Pathogens use previously undescribed mechanism to sabotage host immune system

New research identifies a previously unknown enzymatic mechanism that subverts the early host immune response and promotes pathogenicity by manipulating a common signaling pathway in host cells.

10 Dec 2007